Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Jim Hartnett"'
Autor:
Jonathan Mitchell, Jamison Grailer, Pete Stecha, Jim Hartnett, Frank Fan, Mei Cong, Julia K Gilden
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/db5fdbf8eb45460a9ae4901690563d58
Autor:
Jamison Grailer, Julia Gilden, Pete Stecha, Jim Hartnett, Vanessa Ott, Michael Slater, Dan Lazar, Zhijie Jey Cheng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/e7a26181ad7e4ce1a8140cb45ef98a4e
Publikováno v:
Journal of Immunotherapy. 46:96-106
Autor:
Julia K. Gilden, Pete Stecha, Aileen Paguio, Jim Hartnett, Brock Binkowski, Dan Lazar, Frank Fan, Mei Cong
Publikováno v:
Cancer Research. 83:3202-3202
Despite significant clinical advances in CAR-T cell therapies for cancer, the ability to precisely and reproducibly analyze the potency of these drug products remains a challenge. As new CAR-T products and production methodologies are developed, it i
Publikováno v:
Cancer Research. 83:905-905
Adoptive transfer of T cells genetically modified to express antigen receptor transgenes has shown promise for the treatment of cancer. Both chimeric antigen receptors (CARs) and transgenic T cell receptors (TCRs) have been used to redirect T cells i
Autor:
Jun Wang, Julia Gilden, Denise Garvin, Pete Stecha, Jim Hartnett, Frank Fan, Mei Cong, Jamison Grailer
Publikováno v:
Cancer Research. 83:3274-3274
Programmed cell death protein 1 (PD-1) is an immune checkpoint (IC) receptor that negatively regulates T cell function. Blocking the interaction of PD-1 with its ligands PD-L1 or PD-L2 unleashes the immune system and enhances anti-tumor responses. Im
Autor:
Jun Wang, Julia Gilden, Denise Garvin, Zhi-jie Jey Cheng, Jim Hartnett, Pete Stecha, Jamison Grailer, Mei Cong, Frank Fan
Publikováno v:
Current Protocols. 1
Antibody Fc effector function is one of the main mechanisms of action (MoA) for therapeutic monoclonal antibodies. Measurement of antibody-dependent cellular cytotoxicity (ADCC) is critical for understanding the Fc effector function during monoclonal
Publikováno v:
Cancer Research. 82:605-605
Immune checkpoint (IC) receptors play critical roles in maintaining immune homeostasis and have emerged as proven drug targets for the treatment of various cancers and autoimmune disorders. Monoclonal antibodies (mAb) designed to block immune inhibit
Autor:
Pete Stecha, Jun Wang, Denise Garvin, Julia Gilden, Jamison Grailer, Jim Hartnett, Frank Fan, Mei Cong, Zhi-jie Jey Cheng
Publikováno v:
Cancer Research. 82:4249-4249
Fc effector function is one of the main mechanisms of action (MoA) for therapeutic monoclonal antibodies (mAbs). Quantitative measurement of antibody-dependent cellular cytotoxicity (ADCC) is critically required for understanding the Fc function in m
Autor:
Jamison Grailer, Julia Gilden, Jun Wang, Denise Garvin, Pete Stecha, Jim Hartnett, Steven Edenson, Frank Fan, Mei Cong, Zhi-jie Jey Cheng
Publikováno v:
Cancer Research. 82:1875-1875
Programmed death 1 (PD-1) is an immune checkpoint (IC) receptor that negatively regulates T-cell immune function. Blocking the interaction of PD-1 with its ligand PD-L1 unleashes the immune system and enhances anti-tumor responses. Immunotherapy usin